Log in
NASDAQ:APRE

Aprea Therapeutics News Headlines

$24.66
+0.18 (+0.74 %)
(As of 11/24/2020 12:00 AM ET)
Add
Compare
Today's Range
$23.89
Now: $24.66
$25.05
50-Day Range
$20.01
MA: $23.90
$29.39
52-Week Range
$19.67
Now: $24.66
$53.11
Volume122,514 shs
Average Volume117,870 shs
Market Capitalization$522.47 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Aprea Therapeutics (NASDAQ APRE) News Headlines Today

Source:
SourceHeadline
Aprea Therapeutics (NASDAQ:APRE) Stock Price Up 18.4%Aprea Therapeutics (NASDAQ:APRE) Stock Price Up 18.4%
americanbankingnews.com - November 20 at 6:33 PM
Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare ConferenceAprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference
finance.yahoo.com - November 19 at 11:19 AM
Aprea Therapeutics (NASDAQ:APRE) Shares Up 8.4% on Better-Than-Expected EarningsAprea Therapeutics (NASDAQ:APRE) Shares Up 8.4% on Better-Than-Expected Earnings
americanbankingnews.com - November 10 at 6:25 PM
Aprea Therapeutics (NASDAQ:APRE) Posts Quarterly  Earnings Results, Beats Expectations By $0.18 EPSAprea Therapeutics (NASDAQ:APRE) Posts Quarterly Earnings Results, Beats Expectations By $0.18 EPS
americanbankingnews.com - November 10 at 4:45 PM
Aprea Therapeutics EPS beats by $0.16Aprea Therapeutics EPS beats by $0.16
seekingalpha.com - November 7 at 1:56 PM
Aprea Therapeutics (NASDAQ:APRE) Given Average Rating of "Hold" by BrokeragesAprea Therapeutics (NASDAQ:APRE) Given Average Rating of "Hold" by Brokerages
americanbankingnews.com - November 6 at 5:35 PM
Aprea Therapeutics Reports Third Quarter 2020 Financial Results and Provides Update on Business OperationsAprea Therapeutics Reports Third Quarter 2020 Financial Results and Provides Update on Business Operations
finance.yahoo.com - November 5 at 7:11 PM
Aprea on go with early-stage study with APR-548 in blood disorderAprea on go with early-stage study with APR-548 in blood disorder
seekingalpha.com - October 7 at 9:27 AM
Aprea Therapeutics Appoints Michael A. Kelly to Board of DirectorsAprea Therapeutics Appoints Michael A. Kelly to Board of Directors
marketwatch.com - September 29 at 1:08 PM
Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance ChangesAprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes
finance.yahoo.com - September 18 at 9:47 AM
Aprea Therapeutics to Present at Upcoming Investor ConferencesAprea Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - September 3 at 8:39 AM
Aprea Therapeutics EPS misses by $0.19Aprea Therapeutics EPS misses by $0.19
seekingalpha.com - August 11 at 8:43 PM
Aprea Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on Business OperationsAprea Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on Business Operations
finance.yahoo.com - August 11 at 8:43 PM
Aprea Therapeutics Cancer Therapy Platform Is PromisingAprea Therapeutics Cancer Therapy Platform Is Promising
seekingalpha.com - July 21 at 4:15 PM
Karolinska Development’s portfolio company Aprea Therapeutics expands clinical trial of eprenetapopt for TP53 mutant Acute Myeloid LeukemiaKarolinska Development’s portfolio company Aprea Therapeutics expands clinical trial of eprenetapopt for TP53 mutant Acute Myeloid Leukemia
uk.finance.yahoo.com - July 16 at 6:49 PM
Aprea therapeutics expands enrollment in early-stage study of eprenetapopt in blood cancerAprea therapeutics expands enrollment in early-stage study of eprenetapopt in blood cancer
seekingalpha.com - July 16 at 1:31 PM
Aprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for the Front-Line Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)Aprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for the Front-Line Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
finance.yahoo.com - July 16 at 8:31 AM
Karolinska Development makes a partial sale of its holdings in the portfolio company Aprea Therapeutics and receives a net of SEK 39 millionKarolinska Development makes a partial sale of its holdings in the portfolio company Aprea Therapeutics and receives a net of SEK 39 million
uk.finance.yahoo.com - July 8 at 8:03 AM
BRIEF-Karolinska Development Makes Partial Sale Of Its Holdings In Portfolio Company Aprea TherapeuticsBRIEF-Karolinska Development Makes Partial Sale Of Its Holdings In Portfolio Company Aprea Therapeutics
www.reuters.com - July 8 at 8:03 AM
How Aprea Therapeutics (APRE) Stock Stands Out in a Strong IndustryHow Aprea Therapeutics (APRE) Stock Stands Out in a Strong Industry
finance.yahoo.com - July 1 at 1:09 PM
Aprea Therapeutics Appoints Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to Board of DirectorsAprea Therapeutics Appoints Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to Board of Directors
finance.yahoo.com - June 29 at 8:29 AM
Hedge Funds Warming Up To Aprea Therapeutics, Inc. (APRE)Hedge Funds Warming Up To Aprea Therapeutics, Inc. (APRE)
finance.yahoo.com - June 12 at 6:32 PM
Apreas eprenetapopt shows treatment benefit in blood cancer studyAprea's eprenetapopt shows treatment benefit in blood cancer study
seekingalpha.com - June 12 at 1:32 PM
BRIEF-Aprea Therapeutics Presents Results From French Phase IB/II Clinical Trial Of APR-246 (Eprenetapopt) And AzacitidineBRIEF-Aprea Therapeutics Presents Results From French Phase IB/II Clinical Trial Of APR-246 (Eprenetapopt) And Azacitidine
www.reuters.com - June 12 at 8:32 AM
Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia at the 25th European Hematology Association Annual MeetingAprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia at the 25th European Hematology Association Annual Meeting
finance.yahoo.com - June 12 at 8:32 AM
Aprea Therapeutics (APRE) in Focus: Stock Moves 5.8% HigherAprea Therapeutics (APRE) in Focus: Stock Moves 5.8% Higher
finance.yahoo.com - June 12 at 12:22 AM
Is Aprea Therapeutics Stock a Buy?Is Aprea Therapeutics Stock a Buy?
finance.yahoo.com - June 10 at 12:23 PM
BRIEF-Aprea Completes Full Enrollment Of Phase 3 Clinical Trial In Tp53 Mutant Myelodysplastic SyndromesBRIEF-Aprea Completes Full Enrollment Of Phase 3 Clinical Trial In Tp53 Mutant Myelodysplastic Syndromes
www.reuters.com - June 3 at 11:35 PM
Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS)Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS)
finance.yahoo.com - June 3 at 8:33 AM
Aprea Therapeutics to Present at 2020 RBC Capital Markets Global Healthcare ConferenceAprea Therapeutics to Present at 2020 RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - May 18 at 10:29 AM
Aprea Therapeutics EPS beats by $0.11Aprea Therapeutics EPS beats by $0.11
seekingalpha.com - May 15 at 8:31 AM
Aprea Therapeutics Reports First Quarter 2020 Financial Results and Provides Update on Business OperationsAprea Therapeutics Reports First Quarter 2020 Financial Results and Provides Update on Business Operations
finance.yahoo.com - May 15 at 8:31 AM
Why Aprea Therapeutics (APRE) Stock Might be a Great PickWhy Aprea Therapeutics (APRE) Stock Might be a Great Pick
finance.yahoo.com - May 11 at 5:54 PM
INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Aprea Therapeutics, Inc. for Potential Breach of Fiduciary Duty ClaimsINVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Aprea Therapeutics, Inc. for Potential Breach of Fiduciary Duty Claims
finance.yahoo.com - April 27 at 9:39 AM
BRIEF-Karolinska Development Divests part of its holding in Aprea TherapeuticsBRIEF-Karolinska Development Divests part of its holding in Aprea Therapeutics
www.reuters.com - April 13 at 6:48 PM
Have Insiders Been Buying Aprea Therapeutics, Inc. (NASDAQ:APRE) Shares This Year?Have Insiders Been Buying Aprea Therapeutics, Inc. (NASDAQ:APRE) Shares This Year?
finance.yahoo.com - April 2 at 6:40 AM
BRIEF-Aprea Therapeutics Reports Q4 Loss Per Share $0.64BRIEF-Aprea Therapeutics Reports Q4 Loss Per Share $0.64
www.reuters.com - March 26 at 11:08 PM
Aprea Therapeutics EPS misses by $0.24Aprea Therapeutics EPS misses by $0.24
seekingalpha.com - March 26 at 1:06 PM
APRE.OQ - Aprea Therapeutics Inc Profile | ReutersAPRE.OQ - Aprea Therapeutics Inc Profile | Reuters
www.reuters.com - March 26 at 1:06 PM
Aprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate UpdateAprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
finance.yahoo.com - March 26 at 8:06 AM
Aprea Therapeutics, Inc. Common stock (APRE) Real-Time QuotesAprea Therapeutics, Inc. Common stock (APRE) Real-Time Quotes
www.nasdaq.com - February 12 at 10:24 PM
Aprea Therapeutics, Inc. Common stock (APRE) Press ReleasesAprea Therapeutics, Inc. Common stock (APRE) Press Releases
www.nasdaq.com - February 12 at 5:24 PM
Aprea Therapeutics, Inc. Common stock (APRE) After-Hours QuotesAprea Therapeutics, Inc. Common stock (APRE) After-Hours Quotes
www.nasdaq.com - February 12 at 5:24 PM
Aprea Therapeutics Receives Breakthrough Therapy Designation for APR-246Aprea Therapeutics Receives Breakthrough Therapy Designation for APR-246
www.fool.com - January 30 at 4:14 PM
Aprea Therapeutics nabs accelerated review status in U.S. for APR-246Aprea Therapeutics nabs accelerated review status in U.S. for APR-246
seekingalpha.com - January 30 at 12:17 PM
Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 MutationAprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation
finance.yahoo.com - January 30 at 12:17 PM
Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020
finance.yahoo.com - January 9 at 3:43 PM
Were Hopeful That Aprea Therapeutics (NASDAQ:APRE) Will Use Its Cash WiselyWe're Hopeful That Aprea Therapeutics (NASDAQ:APRE) Will Use Its Cash Wisely
finance.yahoo.com - January 3 at 4:11 PM
We're Hopeful That Aprea Therapeutics (NASDAQ:APRE) Will Use Its Cash WiselyWe're Hopeful That Aprea Therapeutics (NASDAQ:APRE) Will Use Its Cash Wisely
finance.yahoo.com - January 3 at 6:52 AM
Recap and Update of Positive Data from Phase Ib/II Clinical Trials of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2019 American Society of Hematology (ASH) Annual Meeting in OrlandoRecap and Update of Positive Data from Phase Ib/II Clinical Trials of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
finance.yahoo.com - December 12 at 9:06 AM
This page was last updated on 11/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.